Key facts
- Purespring Therapeutics’s last known valuation is $81.6M.
- It has raised $164.7M; the latest was Early Stage VC ($105.8M) in Oct 2024.
- Notable investors include British Business Bank, Sofinnova Partners, Forbion, Gilde Healthcare, University of Bristol — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Purespring Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Purespring Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Purespring Therapeutics
Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. The company offers a podocyte-focused gene therapy platform that directs vectors to glomerular structures, aims to maintain kidney filtration function, concentrates on modulating complement signalling in the glomeruli through its lead program for IgA nephropathy, and advances additional candidates for monogenic podocyte disorders such as NPHS2 nephropathy and glomerular basement membrane deficiencies, enabling nephrologists healthcare providers researchers and patients to access disease-modifying therapeutic approaches aimed at delaying or preventing progression to end-stage renal disease dialysis or kidney transplant.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 50
- Website
- purespringtx.com/
- Ownership
- Privately Held (backing)
Purespring Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Purespring Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Purespring Therapeutics in its N-PORT filings yet. We sweep new filings monthly.